These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 32614506)

  • 41. Recurrence and Survival Outcomes After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Small Bowel Adenocarcinoma.
    Saxena A; Valle SJ; Liauw W; Morris DL
    Anticancer Res; 2017 Oct; 37(10):5737-5742. PubMed ID: 28982894
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cytoreduction and HIPEC in the treatment of "unconventional" secondary peritoneal carcinomatosis.
    Cardi M; Sammartino P; Mingarelli V; Sibio S; Accarpio F; Biacchi D; Musio D; Sollazzo B; Di Giorgio A
    World J Surg Oncol; 2015 Oct; 13():305. PubMed ID: 26493405
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Peritoneal carcinomatosis in colorectal cancer: Defining predictive factors for successful cytoreductive surgery and hyperthermic intraperitoneal chemotherapy - A pilot study.
    Mahmoud AM; Ismail YM; Hussien A; Debaky Y; Ahmed IS; Mikhael HSW; Moneer M
    J Egypt Natl Canc Inst; 2018 Dec; 30(4):143-150. PubMed ID: 30472198
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial.
    Klaver CEL; Wisselink DD; Punt CJA; Snaebjornsson P; Crezee J; Aalbers AGJ; Brandt A; Bremers AJA; Burger JWA; Fabry HFJ; Ferenschild F; Festen S; van Grevenstein WMU; Hemmer PHJ; de Hingh IHJT; Kok NFM; Musters GD; Schoonderwoerd L; Tuynman JB; van de Ven AWH; van Westreenen HL; Wiezer MJ; Zimmerman DDE; van Zweeden AA; Dijkgraaf MGW; Tanis PJ;
    Lancet Gastroenterol Hepatol; 2019 Oct; 4(10):761-770. PubMed ID: 31371228
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hyperthermic intraperitoneal chemoperfusion as a component of multimodality therapy for ovarian and primary peritoneal cancer.
    Magge D; Ramalingam L; Shuai Y; Edwards RP; Pingpank JF; Ahrendt SS; Holtzman MP; Zeh HJ; Bartlett DL; Choudry HA
    J Surg Oncol; 2017 Sep; 116(3):320-328. PubMed ID: 28628712
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Management of colorectal cancer patients at high risk of peritoneal metastases.
    Shariff U; Seretis C; Youssef H
    J BUON; 2015 May; 20 Suppl 1():S71-9. PubMed ID: 26051336
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Risk factors for appendiceal and colorectal peritoneal metastases.
    Enblad M; Graf W; Birgisson H
    Eur J Surg Oncol; 2018 Jul; 44(7):997-1005. PubMed ID: 29576463
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prognostic Implication of KRAS Status after Hepatectomy for Colorectal Liver Metastases Varies According to Primary Colorectal Tumor Location.
    Sasaki K; Margonis GA; Wilson A; Kim Y; Buettner S; Andreatos N; Gani F; Amini N; Spolverato G; Pawlik TM
    Ann Surg Oncol; 2016 Oct; 23(11):3736-3743. PubMed ID: 27352204
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM
    Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Risk of metachronous peritoneal metastases in patients with pT4a versus pT4b colon cancer: An international multicentre cohort study.
    Bastiaenen VP; Aalbers AGJ; Arjona-Sánchez A; Bellato V; van der Bilt JDW; D'Hoore AD; Espinosa-Redondo E; Klaver CEL; Nagtegaal ID; van Ramshorst B; van Santvoort HC; Sica GS; Snaebjornsson P; Wasmann KATGM; de Wilt JHW; Wolthuis AM; Tanis PJ
    Eur J Surg Oncol; 2021 Sep; 47(9):2405-2413. PubMed ID: 34030920
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tumor Sidedness, Recurrence, and Survival After Curative Resection of Localized Colon Cancer.
    Malakorn S; Ouchi A; Hu CY; Sandhu L; Dasari A; You YN; Kopetz ES; Ellis LM; Chang GJ
    Clin Colorectal Cancer; 2021 Mar; 20(1):e53-e60. PubMed ID: 33004292
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Histological subtype and systemic metastases strongly influence treatment and survival in patients with synchronous colorectal peritoneal metastases.
    Simkens GA; Razenberg LG; Lemmens VE; Rutten HJ; Creemers GJ; de Hingh IH
    Eur J Surg Oncol; 2016 Jun; 42(6):794-800. PubMed ID: 27055946
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cytoreductive Surgery and Hyperthermic Intraoperative Chemotherapy for Management of Peritoneal Carcinomatosis.
    Nikeghbalian S; Nikoupour H; Dehghani M; Karami MY; Hemati R
    Arch Iran Med; 2018 Apr; 21(4):158-163. PubMed ID: 29693406
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Development of a Prognostic Nomogram for Patients with Peritoneally Metastasized Colorectal Cancer Treated with Cytoreductive Surgery and HIPEC.
    Simkens GA; van Oudheusden TR; Nieboer D; Steyerberg EW; Rutten HJ; Luyer MD; Nienhuijs SW; de Hingh IH
    Ann Surg Oncol; 2016 Dec; 23(13):4214-4221. PubMed ID: 27027308
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Colorectal Peritoneal Metastases Treated by Perioperative Systemic Chemotherapy and Cytoreductive Surgery With or Without Mitomycin C-Based HIPEC: A Comparative Study Using the Peritoneal Surface Disease Severity Score (PSDSS).
    Baratti D; Kusamura S; Azmi N; Guaglio M; Montenovo M; Deraco M
    Ann Surg Oncol; 2020 Jan; 27(1):98-106. PubMed ID: 31691116
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy versus palliative systemic chemotherapy in stomach cancer patients with peritoneal dissemination, the study protocol of a multicentre randomised controlled trial (PERISCOPE II).
    Koemans WJ; van der Kaaij RT; Boot H; Buffart T; Veenhof AAFA; Hartemink KJ; Grootscholten C; Snaebjornsson P; Retel VP; van Tinteren H; Vanhoutvin S; van der Noort V; Houwink A; Hahn C; Huitema ADR; Lahaye M; Los M; van den Barselaar P; Imhof O; Aalbers A; van Dam GM; van Etten B; Wijnhoven BPL; Luyer MDP; Boerma D; van Sandick JW
    BMC Cancer; 2019 May; 19(1):420. PubMed ID: 31060544
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hyperthermic intraperitoneal chemotherapy plus simultaneous versus staged cytoreductive surgery for gastric cancer with occult peritoneal metastasis.
    Wu X; Li Z; Li Z; Jia Y; Shan F; Ji X; Bu Z; Zhang L; Wu A; Ji J
    J Surg Oncol; 2015 Jun; 111(7):840-7. PubMed ID: 25864884
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Survival and Prognostic Factors for Metachronous Peritoneal Metastasis in Patients with Colon Cancer.
    Nagata H; Ishihara S; Hata K; Murono K; Kaneko M; Yasuda K; Otani K; Nishikawa T; Tanaka T; Kiyomatsu T; Kawai K; Nozawa H; Watanabe T
    Ann Surg Oncol; 2017 May; 24(5):1269-1280. PubMed ID: 27995451
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with or without early post-operative intraperitoneal chemotherapy for appendix neoplasms with peritoneal metastases: A propensity score analysis.
    Soucisse ML; Fisher O; Liauw W; Ghanipour L; Cashin P
    Eur J Surg Oncol; 2021 Jan; 47(1):157-163. PubMed ID: 32943277
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Peritoneal Carcinomatosis of Urachus Origin Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An International Registry of 36 Patients.
    Mercier F; Passot G; Villeneuve L; Levine EA; Yonemura Y; Goéré D; Sugarbaker PH; Marolho C; Bartlett DL; Glehen O;
    Ann Surg Oncol; 2018 Apr; 25(4):1094-1100. PubMed ID: 29238881
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.